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Summary
Burning Mouth Syndrome (BMS) is a difficult 
disease for patients and clinicians. Moreover, 
there is not a general consensus on how to 
treat the disease. The main objective of this 
paper is to evaluate BMS patients’ response 
to topical clonazepam treatment.
A double blind study was performed. Among 
a total of 66 patients, 33 were treated with ta-
blets of clonazepam and another 33 were trea-
ted with a placebo. Symptoms were evaluated 
after 1 month and 6 months of treatment and 
scored on an analogical scale from 0 to 10.
Among the 33 patients treated with clonaze-
pam, 23 showed at least a 50% reduction in 
symptoms after 1 month of treatment. On the 
contrary, only 4 in the placebo group exhibited 
significant improvement. After 6 months, sig-
nificant differences were observed again, as 
23 of the 33 patients treated with the drug re-
ported at least a 50% reduction in symptoms, 
whereas only 2 among those treated with the 
placebo significantly improved. 
However, when measured in terms of a com-
plete cure (lack of symtoms), the differences 
were not significant: 5 drug-treated patients 
and one belonging to the placebo group were 
asymptomatic after one month of treatment. In 
summary, it seems that clonazepam applied 
topically was effective in treating BMS in a lar-
ge proportion of patients.
Resumé
La stomatodynie ou Syndrome des sensations 
de la brûlure buccale (Burning Mouth Syndro-
me, BMS) est une maladie difficile pour les 
patients et les cliniciens. En outre, il n’y a pas 
un consensus général sur la façon de traiter 
la maladie. L’objectif principal de cette étude 
est d’évaluer la réponse des patients atteints 
de BMS à un traitement topique avec clona-
zépam.
Une étude en double aveugle a été réalisée à 
l’aide d’un total de 66 patients, dont 33 ont été 
traités avec des comprimés de clonazépam et 
33 avec du placebo. Les symptômes ont été 
évalués après 1 mois et 6 mois de traitement 
moyennant une échelle analogique allant du 
0 à 10.
Parmi les 33 patients traités par le clona-
zépam, 23 ont montré au moins une réduc-
tion de 50% des symptômes après 1 mois 
de traitement. Au contraire, seulement 4 pa-
tients du groupe placebo présentaient une 
amélioration significative. Après 6 mois, des 
différences significatives ont été observées à 
nouveau, puisque 23 des 33 patients traités 
avec le médicament ont signalé au moins une 
réduction de 50% de leurs symptômes, tandis 
que seulement 2 des les patients traités avec 
le placebo ont noté une amélioration clinique.
Toutefois, lorsqu’on mesure les résultats en 
termes de guérison complète (absence de 
symptômes), les différences n’étaient pas 
significatives: 5 patients traités par le médi-
cament et un seul appartenant au groupe pla-
cebo étaient asymptomatiques après un mois 
de traitement. Ceci nous permet d’affirmer 
que l’application topique du clonazépam a été 
efficace dans le traitement de BMS dans une 
proportion importante des patients.
Introduction
Despite the fact that its causes, pathogene-
sis and even definition are poorly understood, 
Burning Mouth Syndrome (BMS) is a cause of 
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concern for both clinicians and patients, and 
subsequently its treatment is a topic of clinical 
research (1-5). 
The main symptom is a continuous, painful, 
burning sensation in the oral or pharyngeal 
mucosa, without apparent clinical alterations 
(3, 4). This is usually accompanied by some 
other dysesthesia in the mouth, such as a 
sandy feeling or dryness; however, salivary 
flow is often unaffected (4-10). Moreover, pa-
tients frequently report altered taste, such as 
the perception of a metallic or bitter taste (11, 
12). The sensation of burning or stinging can 
be produced in any part of the oral mucosa, 
especially the tongue (on the tip and sides) 
and the lips (6, 12). 
Up to now, there has been no recognized 
treatment for BMS (13). Most affected people 
are postmenopausal women, with strong 
symptoms of anxiety or depression, who are 
often being treated with anxiolytics, antide-
pressants, hypnotics or psychotherapy (7, 8, 
14-16). 
In 2003, Zakwreska et al (15) evaluated pre-
vious research in which patients suffering 
from BMS were treated with antidepressive 
drugs, analgesics, hormonal reposition the-
rapy, vitamins or cognitive therapy; their re-
sults showed that only cognitive therapy had 
a significant effect. In contrast, some authors 
have reported improvement with low doses of 
tricyclic antidepressants (4, 12, 13). In other 
papers, improvement after the use of oral 
benzodiazepines or other anxiolytics (11, 12, 
15), including clonazepam (12, 17) has been 
described. Topical anesthetic solutions can be 
effective in some cases, while in others symp-
toms are exacerbated (18). The topical or sys-
temic administration of capsaicin, a desensiti-
zer, has been also recommended (19, 20). In 
1998, Woda et al reported a 50% reduction on 
a pain scale following the treatment of BMS 
patients by local application of clonazepam 
tablets (21). They suggested that this local 
treatment may affect some unknown etiopa-
thogenic factor in the peripheral nervous sys-
tem. On the basis of these findings, we desig-
ned a clinical study for comparative purposes. 
We treated a group of BMS patients with clo-
nazepam tablets dissolved in the mouth, or 
with a placebo, and subsequently, a clinical 
evaluation of the symptoms in both groups 
was performed.
The main purpose of this study was to evalua-
te BMS patients’ response to locally-applied 
clonazepam treatment.
Material and methods
Patients
Between January 2005 and July 2006, we en-
rolled 66 adults with BMS to participate in a 
randomized clinical trial. The primary aim of 
the study was to examine the effect of locally 
applied clonazepam. Most patients -64- were 
females. Some patients attended the clinic 
to receive dental or medical treatment, while 
others were referred by colleagues after un-
successful treatments. All subjects reported 
oral burning in the absence of apparent oral 
lesions. None of the patients was treated in 
the last month before their inclusion in the stu-
dy.  
We excluded patients with disorders in the 
oral mucosa that could explain the symptoms, 
those who were receiving treatment for BMS 
and those who did not attend the follow-up vi-
sits.
The study did not exclude any patient who 
had an accompanying systemic disease, nor 
those who were receiving treatment for other 
disorders. Subjects taking anxiolytics or an-
tidepressives were not rejected, since there 
is a high prevalence of BMS among patients 
with psychiatric antecedents (21-31).
Methods
A double blind study was performed. Three 
clinicians, with extensive experience in oral 
medicine, examined the patients (they be-
long to the Oral Pathology section, Faculty 
of Dentistry, University of Barcelona; two of 
them have an MD and PhD, are specialists 
in Oral Medicine, and one is a DDS and PhD 
and also a dermatologist). A table of random 
numbers was used in order to ensure the ran-
domization of the treatments. 
The patients were examined in the Section of 
Oral Medicine at the Dental Clinic of the Uni-
versity of Barcelona and in private practice. 
A detailed clinical history was recorded for 
each patient, and a protocol sheet as the one 
used by Woda et al was completed (21). Du-
ring the first visit, the burning presented by the 
patients was recorded using a visual analogic 
scale (VAS) from 0 to 10. The protocol was 
reviewed and approved by the Institutional 
Review Board.
Six variables were recorded for each patient: 
age, sex, duration of disease, location of the 
burning sensation, systemic diseases and 
drugs consumed.
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Before the trial began, the patients were infor-
med of the purposes of the study.  When the 
patients had given their consent, they were 
provided with the tablets.
Study design:  Two groups of patients were 
established at random: Group A: 33 patients, 
treatment group. Each patient was given 
a sealed envelope containing 32 tablets of 
0.5mg of clonazepam. They were instructed 
to take a single tablet at the first sign of dis-
comfort in the morning. The tablet should be 
dissolved in the mouth for three minutes, and 
then the remaining saliva should be spat out. 
The patient should then note his or her sen-
sations and the evolution of the symptoms. If 
there was improvement, the procedure was to 
be repeated when the symptoms reappeared. 
Patients were advised not to exceed four ta-
blets a day (that is, a total dose of 2 mg of 
clonazepam). Group B: 33 patients, placebo 
group. They were given 32 lactose tablets, 
of the same shape and size as those given 
to Group A. Their instructions 
were the same as those given 
to Group A. All the patients 
were scheduled for a visit af-
ter 1 week for the sole purpo-
se of detecting undesirable 
side effects. They were again 
scheduled for visits after 1 
month and 6 months, which 
allowed the clinicians to moni-
tor their evolution. At each vi-
sit, the burning sensation was 
measured on a VAS from 0 to 
10.
Statistical treatment of data: 
The data were processed 
using the SPSS 11.0 for Win-
dows. Results were analyzed 
using the Chi square test. On 
the basis of the data recorded, 
two new variables were crea-
ted for later analysis: More 
than 50% improvement after 
1 month and 6 months, and 
remission after 1 month and 6 
months, defined as a score of 
0 (absence of pain).
Results 
Table 1 shows the data co-
rresponding to the VAS be-
fore the beginning of the 
treatment, after 1 month and 
after 6 months, both for the 
treatment group and for the placebo group. 
Table 2 shows the most representative statis-
tical data for both groups. One can observe 
that the differences between the groups’ ave-
rages were not statistically significant at the 
beginning of the treatment. In contrast, after 
one month, the mean in both groups had de-
creased; the VAS was significant (P<0,005) 
in the clonazepam group whereas it was not 
significant in the placebo group.
Information on the systemic diseases and 
treatments received by the patients is shown 
in Table 3. As can be seen, the most frequent 
disorders present were psychological, hormo-
nal, cardio-circulatory and gastrointestinal di-
seases. A significant number of patients were 
regular consumers of psychoactive drugs.
Their age average was 64,9 (ranging from 48- 
to 85-years-old). The patients were divided 
into three groups: younger than 60, from 60 to 
70, and older than 85 (Figure 1). 
 Information about the pain characteristics, its 
Figure 1. Age and gender of the patients on the treatment and the placebo group.
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Clonazepam Patients Placebo Patients
First Day 1 month 6 months  First Day 1 month 6 months
9 4 3 8 0 2
6 5 4 7 4 4
7 6 5 4 3 3
6 5 3 9 5 5
5 1 2 6 4 4
8 2 5 7 5 5
9 0 2 8 5 5
10 4 4 9 5 5
10 0 0 10 4 6
5 1 3 9 6 6
6 0 2 9 6 6
7 2 3 8 5 5
6 2 4 8 6 6
8 2 3 8 5 5
9 4 3 8 4 6
8 3 3 6 5 4
7 4 3 9 5 5
9 0 0 8 6 5
8 5 3 9 5 5
8 3 4 6 4 4
8 5 6 7 4 4
8 3 3 6 6 6
6 4 4 4 3 3
8 3 3 8 5 5
7 0 0 9 5 5
5 3 3 10 6 6
9 4 3 10 7 6
6 4 5 5 3 3
10 4 2 6 4 4
8 5 4 7 4 4
9 4 3 7 4 4
10 2 3 8 5 5
9 3 2 9 2 3
Table 1. VAS (Visual Analogic Scale) values for the symptoms reported by both patient’s groups.
23
Bull Group Int Rech Sci Stomatol Odontol. 49: 19-29 (2010)
Clonacepan Patients 1st Day
Mean 7,6969697
Standard error 0,26644705
Median 8
Mode 8
Standard deviation 1,53062178
Range 5
Minimun 5
Maximun 10
Sum 254
N 33
Clonacepan Patients 1st Month
Mean 2,84848485
Standard error 0,29555165
Median 3
Mode 4
Standard deviation 1,697815
Range 6
Minimun 0
Maximun 6
Sum 94
N 33
Clonacepan Patients 6st month
Mean 3,03030303
Standard error 0,23631021
Median 3
Mode 3
Standard deviation 1,35749881
Range 6
Minimun 0
Maximun 6
Sum 100
N 33
Placebo Patients 1st Day
Mean 7,57575758
Standard error 0,27534518
Median 8
Mode 8
Standard deviation 1,58173763
Range 6
Minimun 4
Maximun 10
Sum 250
N 33
Placebo Patients 1st Month
Mean 4,24242424
Standard error 0,20884922
Median 4
Mode 4
Standard deviation 1,19974745
Range 6
Minimun 0
Maximun 6
Sum 140
N 33
Placebo Patients 6th month
Mean 4,42424242
Standard error 0,16872013
Median 4
Mode 4
Standard deviation 0,96922337
Range 4
Minimun 2
Maximun 6
Sum 146
N 33
Table 2.  Statistical data of the VAS (visual analogic scale) values reported by both patient’s groups.
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Pathological history (A)
Psycological 
Diseases
Hormonal 
Diseases
Cardiocirculatory
Diseases
Gastrointestinal
Diseases
Placebo group  
(n=33) 20 12 14 18
Treatment group  
(n=33) 21 14 17 20
All patients 
(n=66) 41 (62%) 26 (39%) 31 (47% 36 (55%)
Psycoactive drugs (B)
Hypnotics Anxioltycs Antidepressants
Placebo group 
(n=33) 23 25 18
Treatment group 
(n=33) 23 24 15
All patients 
(n=66) 46 (70%) 49 (74%) 33 (50%)
Other drugs (C)
Digestive Cardiocir-
culatory
treatmens
Diabetes 
pills
Hormonal 
treatment
Analgesic 
drugs
Lipid-
lowering 
drugs
Vitamins
Placebo 
group 
(n=33)
16 14 4 1 16 6 3
Treatment 
group 
(n=33)
18 15 3 3 14 9 2
All pa-
tients 
(n=66)
34 (52%) 29 (44%) 7 (11%) 4 (6%) 30 (45%) 15 (23%) 5 (8%)
Systemic diseases (D)
Psycological 
Diseases
Hormonal 
Diseases
Cardiocirculatory
Diseases
Gastrointestinal 
Diseases
Placebo group
 (n=33) 20 15 16 19
Treatment group
 (n=33) 21 11 15 17
All patients
 (n=66) 41 (62%) 26 (39%) 31 (47%) 36 (36%)
Table 3. Relevant variables recorded from the anamnesis of the patients: Pathological history (A), Psychoactive Drugs usage (B), 
Other drugs usage (C) and Systemic diseases (D).
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location, duration, altering factors and trigger 
factors is shown in Table 4. All the patients 
reported burning on the tongue; the lip area 
was the second location of the symptoms, fo-
llowed by the palate. 88% of the patients re-
ported oral dryness, and the majority of them 
suffered BMS symptoms for more than one 
year.
Table 5 shows the average number of tablets 
taken by each group. It is necessary to note 
that during the first week, consumption in both 
groups was similar. After the second week, 
there was a decrease in the number of tablets 
consumed. This decrease is more apparent, 
although not significant, in the patients who 
were taking clonazepam.
Patients who improved reported that they felt 
the symptoms disappear a few minutes after 
Clinic Characteristics of Pain (A) 
Swelling
sensation Dryness Sandy feeling Burning
Placebo group  (n=33) 10 30 2 33
Treatment group (n=33) 9 28 3 33
All patients (n=66) 19 (29%) 58 (88%) 5 (8%) 66 (100%)
Location (B)
Tongue Palate Gum Oropharyngeal Lips Other
Placebo group
(n=33) 33 16 10 9 20 3
Treatment group 
(n=33) 32 17 8 7 22 4
All patients  
(n=66) 66 (100%) 33(50%) 18(28%) 16 (25%) 42(63%) 7 (11%)
Duration Time (C)
< 6 months  6 to12 months > 12 months
Placebo group (n=33) 2 7 24
Treatment group (n=33) 2 5 27
All patients (n=66) 4 (6%) 12 (18%) 50 (76%)
Altering or Trigger  Factors (D)
Stress Temperature (*) Chewing
Placebo group (n=33) 20 14 21
Treatment group (n=33) 17 15 22
All patients (n=66) 37 (56%) 29 (44%) 43 (65%)
Table 4. Clinic characteristics of pain (A), its location (B), duration time (C) and altering or trigger factors (D) (*) Variation inside 
the oral cavity).
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the tablet was dissolved in their mouths; even 
the dryness and taste alterations reduced. 
Some patients reported a sensation of effer-
vescence and numbness of the tongue when 
the tablet was dissolved. However, symptoms 
reappeared after 3 or 4 hours and a new tablet 
was necessary.  This way, patients were able 
to control the symptoms all day. The only side 
effect registered was some degree of sleepi-
ness in 5 patients of the clonazepam group, 
which did not require the clinicians to suspend 
the treatment.
When the VAS values at the 
beginning and after one mon-
th were compared, it was ob-
served that, of the 33 sub-
jects receiving clonazepam, 
23 showed more than a 50% 
reduction in symptoms, whi-
le only 4 out of the 33 indivi-
duals treated with the placebo 
showed such an improvement 
(Figure 2). This difference was 
statistically significant (p<0.05, 
Chi square). Again, 5 of the 
subjects receiving clonazepam 
were completely cured after 
one month, while complete di-
sappearing of symptoms occu-
rred in only one subject taking 
the placebo (p>0.05). Similarly, 
in a comparison between VAS values at the 
beginning and after six months, of the 33 
patients receiving clonazepam, 23 improved 
more than 50%, while only 2 of those receiving 
the placebo improved (p<0.05). In this case, 
only 3 of the 33 patients who were receiving 
clonazepam were totally asymptomatic, while 
none among those receiving the placebo was 
asymptomatic (p>0.05).
Discussion
Regarding the descriptive data, both groups 
Day 1 Day 2 Day 3 Day 4 Day 5
Treatment group 3,1 3,3 3,1 3,3 3,3
Placebo group 3,1 3,4 3,2 3,2 3,5
Day 6 Day 7 2nd week First month 6th month
Treatment group 3 3,4 19 70 62
Placebo group 3,7 3 21 95 84
Table 5.  Average number of tablets taken by both groups of patients.
Figure 2.  Distribution of the diminution of 50% of the symptoms after one month of 
treatment, according to location.
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appear to be homogeneous (Table 3, 4 and 
Figure 1), and our population group is com-
parable to those described by Woda et al 
(21), Browning et al (22), Brailo et al (23) and 
Gorsky et al (24). Although data referring to 
symptom reduction are valuable in respect to 
the cure, the number of patients was too small 
(n=5); thus, it seems that data concerning the 
disappearance of symptoms should be regar-
ded as a suggestion for future studies. 
After one month of treatment with clonaze-
pam, 70% of our patients showed at least a 
50% reduction of symptoms. In contrast, the 
proportion of patients showing complete re-
mission (15%) is less encouraging. 
 Although most of the patients had been suffe-
ring from BMS symptoms for more than one 
year, those suffering from BMS for a shorter 
period of time experienced a more remarka-
ble reduction of the symptoms. This is con-
sistent with the results obtained by Woda et 
al (21), who also reported better results in pa-
tients with shorter evolution times. This author 
described a reduction in the pain scale avera-
ge, from 6.2 +/- 0.3 to 3 +/-0.5, after 1 month 
of treatment. According to their research, one-
half of their patients were cured, while a third 
experienced remarkable improvement; the 
rest remained as they were at the beginning 
of the study. 
It is also significant that the patients who were 
not suffering from any psychological problems 
had a greater proportion of cures. Numerous 
authors (25-32) have associated BMS with 
certain types of psychiatric disorders, such as 
depression or anxiety. The studies by Lamey 
and Lamb (25) and Lamey and Lewis (33) in 
1989 found that the patients who were suffe-
ring from chronic anxiety were the least likely to 
improve during the treatment. In 1996, Lamey 
claimed an improvement rate of 70% among 
patients in whom diagnosis and treatment of 
other factors were effective (34). Other au-
thors (30-32) concur with Lamey; they believe 
that psychiatric, social or personal problems 
are poor prognostic factors in terms of a cure. 
So, our results are in agreement with those of 
Lamey, who found that patients suffering from 
psychological problems and chronic anxiety 
are more difficult to treat.
On the other hand, the rapid activity of the to-
pical clonazepam, seems to indicate that this 
drug acts locally while dissolving in the mouth, 
acting on some of the peripheral etiopatoge-
nic factors of the BMS.
The same hypothesis is supported by Gre-
meau-Richard et al (35).. In a controlled and 
double blind study, they achieved similar re-
sults and, therefore, suggested that clona-
zepam acts locally, affecting one or more of 
the etiopathogenic mechanisms responsible 
for BMS. This would validate the proposal of 
Grushka et al (36), who stated that BMS ori-
ginates with an alteration in neuronal trans-
mission. These authors note that the sensiti-
ve endings of the tongue responsible for the 
perception of the burning sensation are clo-
sely related to the taste receptors and to the 
sensation of dryness.  The main explanation 
could be that, in some patients, the dryness 
and altered taste improved simultaneously 
with the clonazepam treatment.  
However, it should be noted that the effective-
ness of the clonazepam could be partially attri-
buted to its sublingual absorption, since some 
of the patients experienced sleepiness, as we 
mentioned before. Nevertheless, the rapid re-
duction of discomfort (in less than 10 minutes) 
and the duration of the period in which the 
patient was asymptomatic (3-5 hours) are not 
consistent with data on the pharmacokinetic 
properties of systemic clonazepam. When ad-
ministered orally, clonazepam has a half–life 
of 25 to 60 hours and a serum peak between 
3 and 12 hours due to its hepatic degradation. 
Normally, it takes 3 to 4 hours to exert its phar-
macological effect, which lasts 7-8 hours. 
Both groups of patients showed improvement, 
which was partially due to the psychotherapy. 
The management of patients with BMS should 
be focused on two aspects. On one hand, cli-
nicians could treat the symptoms; on the other 
hand, they could use basic psychotherapy 
customized to each person, which can be ca-
rried out in our dental office. The aforemen-
tioned psychotherapy is focused on listening 
to the patient, emphasizing affectivity, securi-
ty and tranquility, and transmitting the feeling 
that we know exactly what the patient is going 
through as well as the difficulties we face in 
giving him/her solutions to his/her problems.
Our personal experience has shown us that, if 
we manage to calm the patient with our attitu-
de, the possibility of improvement increases; 
this is particularly true in patients who are re-
latively stable from an emotional point of view. 
The improvement was significant at the bein-
ning of our study, but we noted that, in the 
control performed after six months, there was 
a high degree of heterogeneity. There were 
periods of exacerbation of the disease, during 
which time the subjects did not respond in the 
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same way to the medical treatment. Similarly, 
we also have observed periods of improve-
ment, in which taking the drug was not neces-
sary. Looking at the clinical history, it becomes 
clear that most periods of exacerbation coinci-
ded with phases of emotional unbalance. Due 
to these aspects, in the control performed af-
ter six months, we asked the patients to provi-
de us with the average VAS value correspon-
ding to the days immediately before their visit.
Taking into account the results obtained in 
this study, we can conclude that clonaze-
pam applied topically was beneficial for the 
treatment of , in our group of studied patients. 
Further investigations should be carried out 
to explore the etiopathogeny of BMS. These 
studies could lead to the discovery of new and 
more effective treatments.
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